Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dabrafenib in BRAF-mutant metastatic melanoma with brain metastases
2010-023837-45Phase 2Completed
- Sponsor
- GSK
- Start
- Dec 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of dabrafenib + trametinib in melanoma and brain metastases (2 cohorts), sponsored by GSK. Primary endpoint: Overall intracranial response rate. Started Dec 2010; status: completed.
02
Drugs
dabrafenib + trametinib
03
Conditions
melanomabrain metastases
Beyond the preview
Go deeper on 2010-023837-45.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-023837-45.